What is driving VBI Vaccines Inc (NASDAQ: VBIV) stock

Free $100 Forex No-Deposit Bonus

VBI Vaccines Inc (NASDAQ: VBIV) stock surged over 23.2% on 17th July, 2020 leading to a total rise of over 126% in the last four weeks and a rise of 347% YTD driven by the positive developments in the firm.

The firm is also leveraging a proprietary enveloped virus-like particle (eVLP) platform technology to develop next-generation vaccines like VBI-1901 which is GLIOBLASTOMA (GBM) vaccine immunotherapeutic candidate (currently in Phase I/IIa study).  VBI-2901 is PAN-CORONAVIRUS (COVID-19, SARS, MERS) vaccine candidate in development in a collaboration with the National Research Council of Canada while VBI-1501 is Prophylactic CMV vaccine candidate (positive topline Phase I data announced in May 2018). The group saw a positive Part B data from its ongoing Phase 1/2a study of VBI-1901, its cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients. The group confirmed durable partial response with recurrent GBM tumor reduction of more than 50%. The Normal baseline CD4+/CD8+ T cell ratio identified as potentially predictive biomarker associated with tumor responses.  By fourth quarter of 2020, the firm is targeting Clinical study materials to be available for human clinical studies

The firm is well positioned to leverage its major immunology expertise to address unmet medical needs in both INFECTIOUS DISEASE and IMMUNO-ONCOLOGY. They are even advancing prevention and treatment of HEPATITIS B:  Sci-B-Vac® – which is the Only tri-antigenic Hepatitis B vaccine and recently completed a Phase III program in the U.S., Europe, and Canada while approved and marketed in Israel . The group’s VBI-2601 Immuno-therapeutic is in development with a collaboration with Brii Biosciences for a functional cure for chronic Hepatitis B .

Targets for 2020-year end by the firm is solid, for four of its pipeline products. For Sci-B-Vac® which is Hepatitis B Prophylactic Vaccine the firm intends to submit applications for regulatory approvals in the U.S., Europe, and Canada Beginning Q4 2020. For VBI-1901 which is GBM Vaccine Immunotherapeutic (Immuno-Oncology) the firm is targeting Initial immunologic and tumor response data expected from VBI-1901 + AS01B Phase IIa (Part B) study arm by fourth quarter of 2020. For VBI-2601 which is Hepatitis B Immunotherapeutic the firm is targeting Initial human proof-of-concept Phase Ib/IIa data readout by first half of 2020.

Copyright © 2020. All Rights Reserved. FXDailyReport.Com
Risk Warning: Trading CFDs is a high risk activity and you may lose more than your initial deposit. You should never invest money that you cannot afford to lose. FXDailyReport.com will not accept any liability for loss or damage as a result of reliance on the information contained within this website including data, quotes, charts and buy/sell signals. Please be fully informed regarding the risks and costs associated with trading the financial markets.